H-SLLQHLIGL^-OH

Ref. 3D-PP47168

Informations sur le produit

• Nom: H-SLLQHLIGL^-OH

Description

Peptide H-SLLQHLIGL^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SLLQHLIGL^-OH include the following: Abstract B078: GoTCR: Inducible MyD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells and improves antitumor efficacy in T Pentcheva-Hoang, D Torres, T Rodriguez - Cancer Immunology , 2016 - AACRhttps://aacrjournals.org/cancerimmunolres/article/4/11_Supplement/B078/468004 Inducible myD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells and improves anti-tumor efficacy in myeloma T Pentcheva-Hoang, D Torres, T Rodriguez - Blood, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119345513 Inducible MyD88/CD40 enhances proliferation and survival of PRAME-specific TCR-engineered T cells and increases anti-tumor effects in myeloma T Hoang, A Foster , J Crisostomo, A Lu, A Moseley - Blood, 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497118488659 Anti-tumor immunity of gene vaccine with nucleofection technology T Guan, Q Xie, X Yang , G Wang, Z Zhu, J Wang - Clinical Oncology and , 2011 - Springerhttps://link.springer.com/article/10.1007/s11805-011-0565-9 Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes S Sengupta , S Das , AC Crespo , AM Cornel, AG Patel - Nature cancer, 2022 - nature.comhttps://www.nature.com/articles/s43018-022-00427-5 A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies S Rosskopf, J Leitner, W Paster, LT Morton - Oncotarget, 2018 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915142/ An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions S Kramer, A Moritz, L Stehl, M Hutt, M Hofmann - Scientific Reports, 2023 - nature.comhttps://www.nature.com/articles/s41598-023-32384-z PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer RA van Amerongen, S Tuit, AK Wouters - Frontiers in , 2023 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1121973/full Nucleofection of a DNA vaccine into human monocyte-derived dendritic cells Q Xie, J Luo, Z Zhu, G Wang , J Wang , B Niu - Cellular Immunology, 2012 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0008874912000974 Restricted T Cells with Potent Antitumor− PS Allo-HLA - 2011 - academia.eduhttps://www.academia.edu/download/46673224/PRAME-Specific_Allo-HLA-Restricted_T_Cel20160621-29752-11txdpy.pdf Peptide binding specificity of the chaperone calreticulin N Sandhu, K Duus, CS Jorgensen, PR Hansen - et Biophysica Acta (BBA , 2007 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1570963907000702 T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety N Sailer, I Fetzer, M Salvermoser, M Braun - Cancers, 2022 - mdpi.comhttps://www.mdpi.com/2072-6694/14/8/1998 Extracellular Domains of CD8alpha and CD8ss Subunits Are Sufficient for HLA Class I Restricted Helper Functions of TCR-Engineered CD4+ T Cells MM van Loenen, RS Hagedoorn, R de Boer - PLoS , 2013 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0065212 Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells MM Van Loenen, R De Boer , RS Hagedoorn - Gene therapy, 2013 - nature.comhttps://www.nature.com/articles/gt20134 Validation of a high-performance liquid chromatography-tandem mass spectrometry immunopeptidomics assay for the identification of HLA class I ligands suitable for M Ghosh, M Gauger, A Marcu, A Nelde , M Denk - bioRxiv, 2019 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/821249.abstract Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma L Spel , JJ Boelens , DM Van Der Steen, NJG Blokland - Oncotarget, 2015 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742140/ A combined immunopeptidomics, proteomics, and cell surface proteomics approach to identify immunotherapy targets for diffuse intrinsic pontine glioma K Pandey , SS Wang , NA Mifsud , P Faridi - Frontiers in , 2023 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fonc.2023.1192448/full Efficient identification of novel Hla-A* 0201-Presented Cytotoxic T Lymphocyte epitopes in the widely expressed tumor antigen prame by Proteasome-Mediated JH Kessler, NJ Beekman, SA Bres-Vloemans - The Journal of , 2001 - rupress.orghttps://rupress.org/jem/article-abstract/193/1/73/20096 Activated human γΎ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens B Altvater, S Pscherer, S Landmeier - Cancer Immunology , 2012 - Springerhttps://link.springer.com/article/10.1007/s00262-011-1111-6 Immuno-transcriptomic profiling of extracranial pediatric solid malignancies AS Brohl , S Sindiri , JS Wei , D Milewski , HC Chou - Cell reports, 2021 - cell.comhttps://www.cell.com/cell-reports/pdf/S2211-1247(21)01533-3.pdf High Avidity PRAME Specific T Cells Derived From In Vivo HLA Mismatched Transplantation Setting Potentially Useful for Immunotherapeutic Strategies. AL Amir, DM van der Steen, RS Hagedoorn, M Griffioen - Blood, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119568951 PRAME-specific allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer AL Amir, DM van der Steen, MM van Loenen - Clinical Cancer , 2011 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/17/17/5615/76370

• Marque: Biosynth